Long-term survivors in stage IV melanoma: A regional population-based study in France

European Journal of Dermatology

Volumn 19, Issue 1, 2009, Pages 38-43

  Tchen, Tatiana ^a   Léonard, Fabienne ^a   Derancourt, Christian ^a,b   Perceau, Géraldine ^a   Goutorbe, Céline ^a   Reguiaï, Ziad ^a   Bernard, Philippe ^a   Grange, Florent ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

Author keywords

Long term survivors; Stage IV melanoma

Indexed keywords

ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; CISPLATIN; DACARBAZINE; FOTEMUSTINE; INTERFERON; INTERLEUKIN 2; THYROGLOBULIN ANTIBODY;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVOR; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; FRANCE; HUMAN; IMMUNOCHEMISTRY; LIVER LOBECTOMY; LIVER METASTASIS; LUNG LOBECTOMY; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; MELANOMA; SURVIVAL TIME; THUMB AMPUTATION;

EID: 60549110835     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0569     Document Type: Article

References (26)

1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
2. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma ptients with distant metastasis. J Am Coll Surg 1995; 18: 193-2
3. Legho SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol 1997; 24(1 suppl 4): S39-43.
4. Samuel LM, Harvey VJ, Mitchell PL, et al. Phase II trial of procarbazine vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. Eur J Cancer 199A; 30A: 205A-6.
5. Margolin KA, Doroshow JH, Akman SA, et al. Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma. J Clin Oncol 1992; 10: 1574-8.
6. Berd D, Mastrangelo W. Combination chemotherapy of metastatic melanoma. J Clin Oncol 1995; 13: 796-7.
7. Kokoschka EM, Klocker J, Loicht U, et al. Interferon-alpha-carboplatin combination for metastatic melanoma: phase 11 study. Eur J Cancer 1994; 30A(14): 2182-3.
8. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71: 2995-3005.
9. Petit T, Janser JC, Petit JC. Complete remission seven years after treatment for metastatic malignant melanoma. Cancer 1996; 78: 571.
10. Ahmann DL, Creagan ET, Hahn RG, et al. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989; 63: 224-7.
11. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1: 126-34.
12. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16: 1103-11.
13. Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997; 79: 2345-53.
14. Bernard P, Derancourt C, Arnoult-Caudoux E, et al. Association des Dermatologues cle Champagne-Ardenne. Etude prospective de l'incidence des cancers cutanés dépistés en pratique Jermatoloqique clans la région Champagne-Ardenne. Ann Dermatol Venereol 2001; 28: 883-7.
15. Grange F. Epidémiologie du mélanome cutané: données clescriptives en France et en Europe. Ann Dermatol Venereal 2005; 132: 975-82.
16. Satzger I, Schenck F, Kapp A, et al. Spontaneous regression of melanoma with distant metastases- report of a patient with brain metastases. Eur J Dermatol 2006; 16: 454-5.
17. Turk W, Guevara-Patino A, Rizzuto GA, et al. Concommitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200: 771-82.
18. Van Baren N, Bonnet MC, Dréno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005; 23: 9008-21.
19. Salcedo M, Bercovici N, Taylor R, et al. Vaccination of melanoma patients usin dendritic cells loaded with an allogenic tumor cell lysate. Cancer Immunol Immunother 2006; 55: 819-29.
20. Khammari A, Nguyen JM, Pandolfino MC. Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2007; 56: 1853-60.
21. Quereux G, Pandolfino MC, Knol AC, et al. Tissue prognostic markers for adoptive immunotherapy in melanoma. Eur J Dermatol 2007; 17: 295-301.
22. Hsueh EC, Essner R, Foshaq LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with cancer vaccine. J Clin Oncol 2002; 20: 4549-54.
23. Tagawa ST, Cheung E, Banta W, et al. Survival analysis after resection of metastatic disease followed by pepticle vaccines in patients with stage IV melanoma. Cancer 2006; 106: 1353-7.
24. Boasberg PD, Hoon IDS, Piro LD, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermotol 2006; 126: 2658-63.
25. Gogas H, Ionnovich J, Dafni U, et al. Prognostic significance of auto-immunity during treatment of melanoma with interferon. New Engl J Med 2006; 354: 709-18.
26. Vercambre-Darras S, Dubucquoi S, Fajardy I, et al. Does spontaneous auto-immunity improve survival in visceral metastatic melanoma? Br J Dermatol 2007; 157: 413-5.